#China #Shanghai #Mitral Valve #KingstronBio #ProStyle M

KingstronBio's ProStyle M® Valve System Successfully Implanted

On March 12, 2026, a landmark achievement in cardiac surgery was made with the successful implantation of KingstronBio's ProStyle M® Transcatheter Mitral Valve System (ProStyle M®). This innovative procedure was performed under pure ultrasound guidance as part of a national multicenter confirmatory study. The operation was spearheaded by Professors Wang Chunsheng and Wei Lai from the Department of Cardiac Surgery at Zhongshan Hospital, affiliated with Fudan University. This marks not only a significant milestone for the ProStyle M® but also represents the kickoff of an extensive clinical study evaluating its safety and effectiveness across multiple centers.

Previous Studies and Efficacy

Prior to this notable operation, the ProStyle M® had undergone a rigorous two-year First-in-Man (FIM) study that included ten patients averaging 71 years in age. Remarkably, the findings exhibited strong anchoring performance without any regurgitation detected in the subjects. As the clinical investigation advances, further data will emerge to substantiate the safety and efficacy of the ProStyle M® system.

KingstronBio's Commitment to Innovation

KingstronBio Technology, based in Changshu, has made innovation the cornerstone of its mission, focusing intensely on the heart valve sector. The company boasts several patented technologies, including the groundbreaking Micro-Ex™ anti-calcification treatment and the AirBo™ dry storage technology for heart valves. This commitment has enabled the development of an extensive product line aimed at addressing structural heart diseases.

KingstronBio's products include various devices such as artificial bioprosthetic heart valves, valve annuloplasty rings, cardiac surgical biopatches, and preloaded dry transcatheter aortic valves. The overarching goal is to provide enhanced treatment options for patients suffering from moderate to severe mitral regurgitation (MR), a condition recognized as the most prevalent valvular heart disease in China.

Addressing Key Clinical Challenges

The domain of Transcatheter Mitral Valve Replacement (TMVR) has been a trailblazing area within interventional cardiology, yet it faces significant technical obstacles. These challenges include complex anatomical configurations, potential risks of left ventricular outflow tract obstruction, and difficulties in anchoring and sealing artificial valves. The ProStyle M® aims to overcome such hurdles with its eccentric design, which reduces the complexity of the surgical process. The design focuses on cultivating stable anchoring and facilitating good hemodynamic performance, thereby ensuring safer surgical outcomes.

Groundbreaking Patented Technologies

The ProStyle M® uses the exclusive Micro-Ex™ anti-calcification treatment process to effectively cleanse the pericardium, removing residual debris such as phospholipids and glutaraldehyde, which promotes long-term durability of the leaflets. Coupled with the AirBo™ valve dry storage technology, this valve achieves superior durability and biocompatibility, setting a new standard in cardiac treatment.

Looking Forward

KingstronBio is dedicated to ongoing research and development aimed at producing cutting-edge solutions for structural heart diseases. With a research team led by prominent experts, KingstronBio holds numerous patents related to biomaterials and innovative valve technologies. By leveraging these patented technologies and focusing on comprehensive product lines, KingstronBio strives to localize and commercialize its offerings, ensuring more reliable treatment options for patients in China.

KingstronBio’s commitment to passion, innovation, and health demonstrates its future-focused vision in changing the landscape of cardiac care. This advancement not only enhances patient outcomes but also reinforces the company's role as a leader in medical device innovation.